Association between the use of glaucoma medications and mortality

Evidence-Based Ophthalmology

Volumn 11, Issue 3, 2010, Pages 178-179

  Yuen, Darana ^a   Buys, Yvonne ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTAGLANDIN DERIVATIVE;

ADULT; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLAUCOMA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NOTE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

EID: 77954651825     PISSN: 15559203     EISSN: 15559211     Source Type: Journal    
DOI: 10.1097/IEB.0b013e3181e473ab     Document Type: Note

References (5)

1. Müskens RP, Wolfs RC, Witteman JC, et al. Topical beta-blockers and mortality. Ophthalmology. 2008;115:2037-2043.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713, 829-830.
3. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113: 1069-1076. (Pubitemid 43947257)
4. Heijl A, Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268-1279.
5. Stein JD, Newman-Casey PA, Niziol LM, et al. Association between the use of glaucoma medications and mortality. Arch Ophthalmol. 2010;128: 235-240.